CD38 and acute myeloid leukemia: In another study, CD38 CAR‐T‐cell therapy was administered to six patients with AML who relapsed after Allo‐HSCT,65 and the study showed that CR was achieved in four cases, grades 2–3 CRS were seen in 88% of cases, and grades III and IV haematologic toxicity was seen in all three patients.